Becton, Dickinson and Company (NYSE:BDX) EVP Sells $10,499.74 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 58 shares of the business’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $181.03, for a total value of $10,499.74. Following the completion of the transaction, the executive vice president owned 8,302 shares in the company, valued at $1,502,911.06. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Becton, Dickinson and Company Trading Up 2.0%

Shares of BDX opened at $190.90 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a 50 day simple moving average of $188.71 and a two-hundred day simple moving average of $188.20. The firm has a market cap of $54.72 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Hedge funds and other institutional investors have recently modified their holdings of the business. Park National Corp OH grew its position in Becton, Dickinson and Company by 6.9% in the 3rd quarter. Park National Corp OH now owns 45,537 shares of the medical instruments supplier’s stock valued at $8,523,000 after acquiring an additional 2,959 shares during the last quarter. Farmers Trust Co. purchased a new stake in shares of Becton, Dickinson and Company during the third quarter valued at $3,144,000. Praxis Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 32.5% during the third quarter. Praxis Investment Management Inc. now owns 5,871 shares of the medical instruments supplier’s stock valued at $1,099,000 after purchasing an additional 1,441 shares during the period. Cullen Capital Management LLC bought a new stake in Becton, Dickinson and Company during the 2nd quarter valued at about $63,486,000. Finally, Caldwell Trust Co bought a new stake in Becton, Dickinson and Company during the 2nd quarter valued at about $796,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research reports. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler restated a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price on the stock. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.